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Abstract
The aim of this report was to present a case of interference on prothrombin time (PT) test that directed further laboratory diagnostics and resulted 
with final detection of monoclonal gammopathy in an 88-year old man. Routine coagulation testing during medical examination at Emergency 
Department revealed unmeasurable PT (< 7% activity) and activated partial thromboplastin time (aPTT) within reference range. After repeated 
sampling for coagulation testing, PT was unmeasurable again, as well as fibrinogen level (< 0.8 g/L), thrombin time (TT) was significantly prolonged 
(107 seconds) and aPTT was within reference range. In both plasma samples refrigerated at 4 ˚C overnight, white gelatinous precipitate was visible 
between the cell and plasma layers and the presence of monoclonal protein (M-protein) was suggested in our patient. Further laboratory diagno-
stics revealed total serum proteins at concentration of 123 g/L and the presence of M-protein IgG lambda (λ) at concentration of 47.1 g/L. These re-
sults suggested monoclonal gammopathy as an underlying pathophysiological condition in our patient. Activities of coagulation factors II, V, VII and 
X were within reference ranges or increased. These results and correction of unmeasurable PT result to 67% in mixing test with commercial normal 
plasma suggest in vitro rather than in vivo interference of M-protein on PT result. In contrast, significantly prolonged TT results in all analysed sam-
ples suggest impact of M-protein on this global coagulation test due to possible effect on fibrin polymerization. 
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Prothrombin time (PT) is the most frequently per-
formed global coagulation test. It is used for as-
sessment of clotting disorders and monitoring of 
patients taking oral anticoagulant therapy (OAT) 
with vitamin K antagonists (VKAs) (1). In patients 
taking VKAs, unmeasurable PT test result is fre-
quently found due to over-anticoagulation caused 
by excessive drug dosing (2). Unreliable, incorrect 
and even unmeasurable PT result in a patient tak-
ing VKAs as well as in a patient not taking any anti-
coagulant therapy, may be caused by inadequate 
or improper sample for coagulation testing or by 
endogenous or exogenous interferences. In gen-
eral, endogenous interferences are usually caused 
by haemolysis, lipemia and hyperbilirubinemia. 
Rarely, monoclonal protein (M-protein) can be the 
cause of endogenous interference on coagulation 
and other laboratory test results due to high sam-
ple viscosity, precipitation and reaction with rea-
gent components (3). In contrast, drugs are com-
mon cause of exogenous interferences (4). Test re-
sults altered by undetected interferences repre-
sent potential danger (5). They are misleading to 
the clinician and the patient is exposed to risk of 
unfavourable outcome, especially in emergency 
care setting.
Although it is known that M-proteins can cause 
abnormal laboratory results, the impact of M-pro-
tein on coagulation test results is different in indi-
vidual patients (6). 
The aim of this study was to present a case of in-
terference of M-protein on PT and other coagula-
tion test results. 
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Materials and methods
Venous blood samples for laboratory testing were 
collected in Vacuette tubes (Greiner Bio-One, 
Kremsmünster, Austria) containing 3.2%-trisodium 
citrate (coagulation testing, volume 1.8 mL), K3ED-
TA (haematology, volume 2 mL), a clot activator 
and Li-heparin (biochemistry, volumes 7 and 5 mL, 
respectively). Patient samples were collected by ve-
nepuncture at the Emergency Department (ED) and 
immediately delivered to the laboratory for analy-
sis. All samples (except for CBC) were centrifuged at 
room temperature for 10 minutes at 1800 x g.
Coagulation tests were performed on Behring Co-
agulation System XP (BCSXP) analyser (Siemens, 
Marburg, Germany) using original manufacturers´  
reagents. PT and activated partial thromboplastin 
time (aPTT) tests were determined by coagulo-
metric method using recombinant human throm-
boplastin reagent Dade Innovin and Actin FS rea-
gent, respectively. TT was measured by coagulo-
metric method with BC Thrombin reagent and fi-
brinogen activity was determined by Clauss clot-
ting method with Multifibren U reagent. The coag-
ulation factors II, V, VII and X were determined by 
one-stage coagulometric methods using PT rea-
gent (Dade Innovin) and appropriate factor defi-
cient plasmas. PT mixing test was performed by 
mixing one part of patient plasma with one part of 
commercial normal plasma (1+1). Coagulation tests 
were performed within 4 hours from blood sam-
pling, except in sample designated as 3*. 
Complete blood count (CBC) was performed on 
DxH 800 automated haematology analyser (Beck-
man Coulter, Brea, CA, USA).
Total protein and β2-microglobulin concentrations 
were quantified on Architect c8000 (Abbott, Wies-
baden, Germany) using total protein reagent (Ab-
bott Laboratories, Abbott Park, IL, USA) and Quan-
tia ß2-Microglobulin (Biokit, S.A., Barcelona, Spain). 
Serum protein electrophoresis was performed us-
ing Capillarys (Sebia, Evry Cedex, France) while im-
munofixation was done on Hydrasys (Sebia, Evry 
Cedex, France).
The patient signed the written informed consent 
for the publication of this report according to the 
ethical guidelines following the Declaration of Hel-
sinki. The institutional ethic committee has also 
approved our study protocol.
Case report
An 88-year-old male presented to ED of the Medi-
cal School University Hospital Sestre milosrdnice, 
Zagreb where he underwent medical examination 
due to general weakness and fresh blood appear-
ance during nose-blowing over the past 10 days. 
The patient denied spontaneous nose bleeding 
(epistaxis). He was suffering from hypertension for 
years and regularly took antihypertensive medica-
tion (ramipril/hydrochlorotiazide). During medical 
examination the patient was conscious, lucid, mo-
bile and afebrile. Standard emergency laboratory 
tests panel was required. Performing of the bio-
chemical analysis was not possible due to the high 
viscosity of the serum sample and repeated cen-
trifugation was done. Since the repeated centrifu-
gation did not gain adequate serum sample, plas-
ma sample venepuncture was asked for. Plasma 
sample did not show the appropriate viscosity for 
the biochemical test analysis. If the serum/plasma 
sample viscosity is too high, analyser would report 
“aspiration error” and processing of sample must 
be cancelled. Coagulation test results showed un-
measurable result for PT (< 7%) and aPTT within 
reference range (24 s; ratio 0.8) as presented in Ta-
ble 1 (sample 1). The patient denied use of any anti-
coagulant medication and a new sample for coag-
ulation testing was requested. Beside PT and aPTT, 
which showed similar results as in the previous 
sample, fibrinogen and TT were additionally meas-
ured. Fibrinogen level was unmeasurable while TT 
was significantly prolonged (Table 1, sample 2). The 
patient was under observation for the next seven 
hours from his admittance to ED. He received a sin-
gle dose of intravenous vitamin K immediately af-
ter the unmeasurable PT result was obtained in 
sample 2. The third sample for coagulation testing 
was taken five hours after vitamin K administration. 
The result for PT was < 7% again and result for aPTT 
was within normal range (Table 1, sample 3). 
Since citrate plasma samples showed an unusual 
opalescence, both samples (sample 2 and sample 
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Sample 1 Sample 2 Sample 3 Sample 3* Sample 4 Sample 5 Reference range










June 2nd at 
23 pm and 
stored at 4 ˚C 
overnight
June 3rd at 
06:30 am
June 3rd at 06:30 
am and incubated 
at 37 ˚C for 30 
minutes
Prothrombin time (PT) 
(%) < 7 < 7 < 7 55 < 7 < 7 ≥ 70
PT mix test with 
normal plasma (1+1) 
(%)
NP NP NP NP 67 NP NA
APTT (s, ratio) 24 (0.8) 25 (0.90) 27 (1.0) 25 (0.90) 29 (1.0) 25 (0.9) 23–32 (0.8–1.2)
Fibrinogen (g/L) NP < 0.8 NP 3.1 < 0.8 < 0.8 1.8–3.5
TT (s) NP 107 NP 56.3 97.4 112 14–21
FII (%) NP NP NP 139 118 NP 70–120
FV (%) NP NP NP 154 129 NP 70–140
FVII (%) NP NP NP 148 151 NP 70–120
FX (%) NP NP NP 185 210 NP 70–120
Sample 3* represents sample 3 which was refrigerated until next morning when PT, aPTT, fibrinogen, TT and FII, FV, FVII and FX 
activities were performed in plasma layer separated from visible precipitate. The results obtained in sample 3* were not reported 
to the clinician due to unmet pre-analytical requirements for coagulation testing.
APTT – activated partial thromboplastin time, TT – thrombin time, NP - not performed, NA – not applicable.
Table 1. Coagulation test results obtained at different time points in a patient with detected M-protein IgG-λ type.
3) were refrigerated (at 4 ˚C) overnight. The next 
morning these refrigerated plasma samples were 
visually inspected and precipitate with gelatinous 
appearance between the cell and plasma layers 
was visible. Plasma layer above precipitate was 
separated from sample 3 and the global coagula-
tion tests (PT, aPTT, TT and fibrinogen) were deter-
mined (Table 1, sample 3*). In this sample the re-
sults of PT and fibrinogen were 55% and 3.1 g/L, 
respectively. Additional measurements of coagula-
tion factor II, V, VII and X activities in this sample 
were also performed. The results for factor activi-
ties showed normal or increased values (Table 1, 
sample 3*). During night the patient was kept un-
der observation and the next morning a new sam-
ple for global coagulation tests was sent to the 
laboratory. The results for PT and fibrinogen were 
unmeasurable again, while aPTT result was within 
reference range and TT was prolonged (97.4 s), as 
shown in Table 1, sample 4. 
PT mixing test showed a correction of PT result to 
67%. In order to investigate the cause of unmeas-
urable PT result, coagulation factor activities were 
also determined in sample 4 and the values were 
comparable with those obtained in plasma sam-
ple after refrigeration (sample 3*). One plasma 
portion of sample 4 was also incubated for 30 min-
utes at 37 °C and the results of global coagulation 
tests were as follows: unmeasurable PT and fibrin-
ogen, prolonged TT and aPTT within reference 
range (Table 1, sample 4).
The visual inspection of plasma sample after over-
night refrigerating as well as the results of coagu-
lation testing described above suggested the pos-
sible presence of plasma precipitate of cryoglobu-
lin type. Therefore, further laboratory diagnostics 
was focused on serum protein electrophoresis and 
immunofixation of serum and heparin plasma left-
overs (Figure 1). The serum sample was incubated 
30 min at 37 °C prior processing into Capyllaris and 
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agarose gel. The plasma and sera samples were 
processed on Architect c8000 as stat samples. An-
alyser signalized inability for measurement due to 
high viscosity of sample, so serum and plasma 
were diluted (4x for total protein and 10x for β2-
microglobulin) with preheated saline prior pro-
cessing. Total serum protein concentration was 
123.0 g/L (reference range 66 - 80 g/L) and serum 
protein electrophoresis showed a monoclonal 
peak at a concentration of 47.1 g/L. Plasma β2-
microglobulin concentration was 17.36 mg/L (ref-
erence range 0 - 2 mg/L). Immunofixation identi-
fied monoclonal IgG - lambda (M-IgG-λ) (Figure 2).
Discussion
We have described a case report of abnormal co-
agulation test results, i.e. unmeasurable PT and fi-
brinogen level with significantly prolonged TT and 
aPTT within reference range in an 88-year old man 
who presented to ED. These abnormal coagulation 
test results in a patient not taking any anticoagu-
lant therapy as well as visual inspection of plasma 
Figure 1. Serum tube centrifuged within one hour from blood 
sampling showed visible gelatinous precipitate after overnight 
refrigeration.
Figure 2. Serum electrophoresis detected M-protein in gamma fraction (a) and immunofixation identified monoclonal immuno-
globulin G lambda (b).
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sample after overnight refrigerating have suggest-
ed the presence of M-protein in circulation. Fur-
ther laboratory diagnostics confirmed the pres-
ence of M-protein IgG-λ and possible diagnosis of 
monoclonal gammopathy. Unfortunately, since 
the patient refused hospitalization after medical 
examination in the ED, it was not possible to set a 
definitive diagnosis. However, on the basis of spe-
cific additional laboratory diagnostic work-up, a 
monoclonal gammopathy as an underlying patho-
physiological condition can be argued in our pa-
tient.
Clinical manifestations of monoclonal gammopa-
thies are heterogeneous and include monoclonal 
immunoglobulin production, decreased immuno-
globulin secretion by normal plasma cells, im-
paired haematopoiesis with anaemia, defect in 
haemostasis, osteolytic bone lesions, hypercalcae-
mia and renal dysfunction (7). 
Haemostatic disorders include both, thrombotic 
and haemorrhagic disorders (8-10). The monoclo-
nal protein itself may have intrinsic prothrombotic 
properties (8,11). Haemorrhagic disorders in pa-
tients with monoclonal gammopathies can be re-
sult of various mechanisms, including factor defi-
ciencies due to amyloid adsorption, M-proteins 
with inhibitory activity to coagulation factors, im-
paired fibrin monomer polymerization or systemic 
fibrinolysis (12). The extent of bleeding correlates 
with the M-protein concentration in plasma, sug-
gesting that the M-protein may be important in 
the pathophysiology of the haemorrhagic diathe-
sis. Abnormal screening coagulation test results, 
such as PT, aPTT and TT are common in patients 
with plasma cell neoplasms (13). However, patho-
logical results for coagulation tests are not always 
associated with clinically significant bleeding. The 
nature and the extent of impact and interference 
on coagulation test results are different in individ-
ual patients with monoclonal gammopathies (6). 
In the patient described in this study PT was un-
measurable, but activities of coagulation factors II, 
V, VII and X in the same sample showed normal or 
even increased values. These results suggest that 
unmeasurable PT result was not due to decreased 
factor activities. Correction of PT result to 67% in 
mixing test further excluded an inhibitory effect of 
M-protein on coagulation factors. Further, TT re-
sult was prolonged in all plasma samples. The 
common causes for TT prolongation are: de-
creased fibrinogen concentration, dysfibrinogene-
mia, increased fibrin/fibrinogen degradation prod-
ucts and heparin or other circulating anticoagu-
lants (14). Since the patient had a normal fibrino-
gen level, as shown in plasma sample after sepa-
rating precipitate layer, hypofibrinogenemia could 
not be considered as the cause of TT prolongation 
in this case. On the other hand, it is known that M-
protein can inhibit fibrin polymerization resulting 
in prolonged TT and abnormal clot formation (15). 
It has been shown that prolonged TT was com-
monly encountered abnormal clotting time test 
result in patients with monoclonal gammopathies 
(6,13,16). In the Pandey`s study prolongation of TT 
correlated with serum immunoglobulin concen-
trations. Despite the relatively frequent abnormal 
TT result, clinical bleeding manifestations were 
observed only in a minority of patients who possi-
bly have other associated haemostatic defects. It is 
known that abnormally high concentrations of M-
protein and associated increased blood viscosity 
can also impair fibrin polymerization (17,18). There-
fore, we suspect that the coagulation abnormality 
that could be the most closely associated with 
nose-bleeding symptom in our patient was the 
prolongation of TT rather than PT. High concentra-
tion of IgG M-protein detected in our patient could 
be responsible for inhibition of fibrin polymeriza-
tion thus accounting for the patients´  clinical 
symptom of fresh blood occurrence during nose 
blowing.
According to the present literature data, it is obvi-
ous that monoclonal gammopathies produce a 
heterogeneous pattern of impacts and interfer-
ences on individual coagulation test results and 
that abnormal result of global coagulation test 
does not necessarily indicate pathological result. 
The results of different studies indicate that mono-
clonal immunoglobulins may target any of hae-
mostatic components. Therefore, further evalua-
tion for individual patient should be guided ac-
cording to the coagulation abnormalities identi-
fied in the laboratory. It can be assumed that 
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thromboelastometry as a method of whole blood 
coagulation testing could be potentially helpful in 
eliciting normal in vivo coagulation in our patient 
with unmeasurable PT result. However, this meth-
od was not available in our laboratory.
The main limitation of this case study was that we 
were not able to monitor patient during his treat-
ment since he refused hospitalization. Because of 
limited quantity of sample, we were not able to 
perform further laboratory diagnostics, like meas-
urement of free light chains. Furthermore, when 
cryglobulin was suspected, there was no possibili-
ty for repeated sampling and transport at 37 °C or 
for the investigation for rheumatoid factor as a po-
tential cause of interference on the coagulation 
test results. 
It should be emphasized that none of the results 
obtained in the sample 4 was reported to the clini-
cian since it did not meet pre-analytical require-
ments for coagulation testing. However, the visual 
inspection as well as coagulation testing of this 
sample had a considerable impact on the clarifica-
tion of our patient case in both, directing the fur-
ther laboratory diagnostics, as well as understand-
ing the nature of impact and interference of M-
protein on individual coagulation tests.
In conclusion, our case study revealed interference 
of M-protein on coagulation test results. The re-
sults are misleading to the clinician and the pa-
tient is exposed to risk of unfavourable outcome in 
case of inappropriate therapeutic intervention, 
such as vitamin K administration in our patient. 
A message arising from this case study is that labo-
ratory evaluation of potential presence of M-pro-
tein in circulation should be considered as the 
next diagnostic step in a patient not taking any 
anticoagulant therapy but with unexplained and 
unexpected coagulation test results. At first, re-
peated blood sampling at 37 °C should be consid-
ered. The next step should be refrigeration of the 
plasma sample overnight at 4 °C in order to in-
spect for the potential presence of M-protein that 
precipitate at cold temperatures. In case of any 
suspicion of the presence of paraproteins in circu-
lation, further diagnostic approach should include 
measurements of total protein concentration, im-
munoglobulins G, A and M, protein electrophore-
sis and immunofixation and β2-microglobulin, if 
possible. 
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